Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan

Qianyun Liu^{1, 5}, Qing Xiong^{1, 5}, Fanghua Mei^{2, 5}, Chengbao Ma¹, Zhen Zhang¹, Bing Hu², Junqiang Xu², Yongzhong Jiang², Faxian Zhan², Xianying Chen¹, Ming Guo¹, Xin Wang¹, Yaohui Fang³, Shu Shen³, Yingle Liu¹, Fang Liu¹, Li Zhou¹, Ke Xu¹, Changwen Ke⁴, Fei Deng³, Kun Cai²✉, Huan Yan¹✉, Yu Chen¹✉, Ke Lan¹✉

¹State Key Laboratory of Virology, Institute for Vaccine Research and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China.

²Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.

³National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences.

⁴Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.

⁵These authors contributed equally: Qianyun Liu, Qing Xiong, Fanghua Mei

✉e-mail: ckreal@163.com; huanyan@whu.edu.cn; chenyu@whu.edu.cn; klan@whu.edu.cn

Abstract

Most COVID-19 patients can build effective humoral immunity against SARS-CoV-2 after recovery(1, 2). However, it remains unknown how long the protection can maintain and how efficiently it can protect people from the reinfection of the emerging SARS-CoV-2 variants. Here we evaluated the sera from 248 COVID-19 convalescents around one year post-infection in Wuhan, the earliest epicenter of SARS-CoV-2. We demonstrated that the SARS-CoV-2 immunoglobulin G (IgG) maintains at a high level and potently neutralizes the infection of the original strain (WT) and the B.1.1.7 variant in most patients. However, they showed varying degrees of efficacy reduction against the other variants of concern (P.1, B.1.525, and especially B.1.351) in a patient-specific manner. Mutations in RBD including K417N, E484K, and E484Q/L452R (B.1.617) remarkably impair the neutralizing activity of the convalescents' sera. Encouragingly, we found that a small fraction of patients' sera showed broad neutralization potency to multiple variants and mutants, suggesting the

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

mutation sites. Our results suggest that the SARS-CoV-2 vaccination effectiveness relies more on the timely re-administration of the epitope-updated vaccine than the durability of the neutralizing antibodies.

Main

The SARS-CoV-2 emerged more than a year ago rapidly swept across the world and developed into a long-lasting COVID-19 pandemic with devastating impacts(3, 4). The situation leads to the perpetual mutation of SARS-CoV-2 with numerous variants emerging around the world. In addition to the initial D614G mutation, the viral spike protein undergone antigenic drift and produced several variants of concern associated with local outbreaks, such as B.1.1.7 (United Kingdom)(5), B.1.351 (South African)(6), P.1 (Brazil, also known as B.1.1.28.1)(7), B.1.525 (Nigeria)(8) and B.1.617 (India)(9).

So far, due to the lack of sufficient evidence about how long the anti-SARS-CoV-2 protective immunity induced by prior infection or vaccination can maintain, the optimal interval between the vaccinations remains to be determined(10, 11). Additionally, increasing evidence showing these variants of concern, especially the South African strain B.1.351(12, 13), remarkably increased resistance to the neutralizing antibodies, which largely due to the mutations in the RBD region interacting with human angiotensin-converting enzyme 2 (hACE2)(3). It is imperative to figure out the durability and cross-variant protection of SARS-CoV-2 neutralizing antibodies elicited by previous infection or vaccination based on the original strain.

Wuhan is the first known epicenter of the SARS-CoV-2 outbreak. Almost all patients in this city were infected by the original strain before the city reopen and the epidemic here had been well controlled thereafter before the emergence of variants(14). In this study, sera from convalescents infected around one year ago in Wuhan were collected to investigate the SARS-CoV-2 antibody durability and the cross-variant protection over time. Results from Enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assay demonstrated that the SARS-CoV-2 RBD-specific IgG antibodies remain detectable in most patients, which potentially inhibit the infection of the SARS-CoV-2 pseudovirus (WT-D614G and B.1.1.7), but to a different extent compromised to other tested variants (P.1, B.1.525 and especially B.1.351) and mutations (K417N, L452R, E484K, and E484Q/L452R). The decline of neutralizing activity was confirmed by authentic viral neutralization assays (WT, B.1.1.7 and B.1.351). Of note, we showed eight individuals developed relatively broad immunity against the tested variants, supporting the presence of broadly neutralizing epitopes. Overall, these results provided important implications for the control of the pandemic caused by the constantly emerging SARS-CoV-2 variants.

Durability and neutralizing activity

To evaluate the durability and neutralizing activity of SARS-CoV-2 antibodies after infection, we collected sera and clinical records from 248 COVID-19 patients infected around one year ago (11-12 months after symptom onset) in Wuhan. Firstly, a rapid ELISA (colloidal gold) test for SARS-CoV-2-S IgM/IgG antibody was applied.

75 79 % (197/248) of the sera tested positive for anti-SARS-CoV-2 IgG, and 2.0 %
76 (5/248) tested positive for anti-SARS-CoV-2 IgM (Table S1). Conventional ELISA
77 assays were then conducted to determine the anti-RBD IgG level and the competitive
78 ability of ACE2 to RBD-binding of the sera. As we set OD450=0.31 (the mean
79 OD450 value + 3 SD of uninfected people's sera) as the cut-off value, 91 % (225/248)
80 tested positive for anti-SARS-CoV-2-RBD IgG (**Fig. 1A**). Our results also showed
81 that the competitive ability is highly consistent with the anti-RBD IgG level (**Fig.**
82 **1A-E**, Table S1), indicating most RBD-targeting antibodies in the patients can
83 interfere with the interaction between ACE2 and RBD. However, the anti-RBD IgG
84 level and the neutralizing activity of the sera showed no statistically significant
85 difference in patients with different severity (Fig.1a-b), gender (Fig.1c-d), and age
86 (Fig. 1e).

87 The neutralizing activities of the sera were tested with SARS-CoV-2 pseudovirus
88 (WT-D614G) produced based on a replication-deficient VSV pseudotyping system
89 (VSV-dG-Luc) and a BHK-21 cell line stably expressing hACE2 (BHK-21-hACE2).
90 234 sera (94 %) showed more than 50 % neutralization when diluted at 20-fold
91 ($NT_{50} > 20$), and 195 samples (79 %) showed 50 % neutralization under 100-fold
92 dilution ($NT_{50} > 100$). No statistically significant difference was observed between
93 pseudovirus neutralizing activity and the disease severity (Fig. 1f). These results
94 indicate that most patients could build and maintain an effective humoral immunity
95 against SARS-CoV-2 for at least one year.

Cross-variant protection

Recently, SARS-CoV-2 variants with multiple mutations in S protein have emerged in the United Kingdom (B.1.1.7), Brazil (P.1), Nigeria (B.1.525), South Africa (B.1.351), United states (B.1.427/B.1.429)(15), India (B.1.617), *etc.* We first tested the neutralizing activity of the top 180 potent sera in Fig. 1f by the pseudoviruses of four variants, with the WT-D614G as a control (Fig. 2a). When tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G is 65 %. However, the efficiency reduced to 59 % for B.1.1.7, 48 % for P.1, 43 % for B.1.525, and 35 % for B.1.351 (Fig. 2b). Interestingly, we found that a small fraction of the patients showed cross-variant neutralizing activity. Accordingly, we selected eight representative sera from those patients (group 1, relatively resistant) for further verification by NT₅₀ determination, with another eight sera (group 2, relatively sensitive) for comparison. As expected, the sera in group 1 showed only a slight decrease in NT₅₀ against the tested variants compared with WT-D614G (1.26~2.57 folds), while the sera in group 2 showed much higher sensitivity (1.83~8.10 folds). The NT₅₀ data further confirmed that the B.1.351 is the top immune escape variant among the tested strains, followed by B.1.525, P.1, and B.1.1.7, respectively (Fig. 2c-d, and Extended data 1a).

We further tested whether the immune escape of the tested variants is mainly attributed to the reduced neutralizing activity of SARS-CoV-2 RBD-specific antibodies. Five C57BL/6 mice were immunized three times with WT SARS-CoV-2 RBD human IgG-Fc recombinant protein. Seven weeks later, the mice sera were

collected and tested by pseudovirus neutralization assay. Similar to most of the convalescents' sera, the sera from RBD protein immunized mice were sensitive to B.1.525, P.1, and B.1.351, but not B.1.1.7, which is reasonable as B.1.1.7 only have one mutation (N501Y) in the RBD region, a mutation without prominent immune escape effect(12, 16) (Fig. 2e). These results showed that the immune escape ability of the variants can be largely attributed to the mutations in the RBD region.

To define the contribution of the critical mutations in RBD region to immune escape, we produced pseudovirus bearing SARS-CoV-2 S protein (D614G) with K417N, L452R, E484K, and L452R/E484Q mutations, respectively. Notably, L452R and L452R/E484Q are two critical mutations in the B.1.427/B.1.429 (The United States) and B.1.167 (India) variant, respectively. We tested the neutralizing activity of the 180 sera by these mutants with the WT-D614G as a control. As shown in Fig. 2f, when tested at 100-fold dilution, the mean neutralization efficiency of the sera against WT-D614G is 69 %. However, the efficiency reduced to 61 % for L452R, 55 % for K417N, 54 % for E484K, and 52 % for L452R/E484Q. This result indicates that the RBD mutations are responsible for the reduction of cross-variant neutralization among the variants of concern, especially mutations on E484 and K417.

Verification by authentic viruses

To confirm whether the neutralization results are consistent between the SARS-CoV-2 pseudovirus and the authentic virus, we first conducted the authentic SARS-CoV-2 virus (WT) neutralization assay to verify the 30 representative sera

showing high, medium, and low neutralizing activities in Fig. 1f, respectively. The SARS-CoV-2 nucleocapsid (N) protein immunofluorescence assay showed consistent results with the pseudovirus neutralization assay (Fig. 3a).

We further verified the neutralizing activity of two groups of patients in Fig. 2 c-d (relatively sensitive and relatively resistant) by three authentic SARS-CoV-2 strains, including the WT strain and the B.1.1.7 and B.1.351 variant strains. The sera were diluted 100-fold, pre-incubated with these viruses, and then applied to Vero E6 cells for infection neutralization assay. As shown in Fig. 3b, the neutralizing activity of the sera against the B.1.1.7 strain is similar to the WT strain but with a slight decrease. As for the B.1.351 strain, the group 1 sera (relatively resistant) efficiently neutralized the infection of both the WT and the B.1.351 strains. In contrast, the group 2 sera (relatively sensitive) showed a remarkable reduction of neutralizing activity against the B.1.351 strain compared with the WT strain (Fig. 3c). Again, these results are also consistent with the results from pseudovirus neutralization assays.

Discussion:

Previous studies show the protective immunity against seasonal coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1) may last only 6 to 12 months(17), and the titer of SARS-CoV-2 antibody has been reported to decline rapidly in the first several months(10), raising the concern about the durability of SARS-CoV-2 neutralizing antibodies elicited by either previous infection or vaccination. Additionally, SARS-CoV-2 variants are constantly emerging during the

COVID-19 pandemic, greatly challenging the development and application of effective neutralizing antibodies and vaccines. It is imperative to investigate the durability and cross-variant protection of the anti-SARS-CoV-2 humoral immunity. To this end, we collected convalescent sera in Wuhan in consideration of the several unique advantages over the samples collected elsewhere: (1) Wuhan is the earliest reported epicenter of COVID-19 with most patients infected more than one year ago; (2) The patients were all infected by the original WT strain without the interference of potential multi-variants infection; (3) So far, most administrated vaccines globally were designed based on the sequences of the original strain from Wuhan.

Firstly, we report that the effective neutralizing antibodies against SARS-CoV-2 could last at least one year in most COVID-19 convalescents, while no statistical significance was observed among different severity, gender, or age (Fig. 1a-e). These results indicate that most people including asymptomatic and elderly patients could build and maintain effective anti-SARS-CoV-2 humoral immunity, with a few exceptions in each group for unknown reasons (Fig. 1). We speculate this phenotype might be attributed to the individual immune difference that deserves further study.

Another particular concern is the cross-variant protective efficacy of the anti-SARS-CoV-2 humoral immunity. Our study provides additional evidence that most sera collected from convalescents in Wuhan, even for one year post-infection, can still efficiently neutralize the infection of B.1.1.7 variant. However, a significant decline of efficacy was observed on P.1, B.1.525, and B.1.351 (Fig. 2b). B.1.351 displayed the most prominent immune escape ability among these tested variants,

consisting with the previous reports(12, 13, 18). Encouragingly, sera from a few individuals showed resistance to all tested variants (Fig. 2c), indicating the presence of effective and broadly neutralizing antibodies. It brings hope for the identification of ideal broad neutralization epitopes essential for the development of antibody therapy and next-generation vaccines.

We next sought to characterize the critical residues that contribute to the immune escape. Based on previous studies and our neutralization results from RBD vaccinated mouse sera, we focus on the four mutation sites in RBD of the tested variants in this study (Fig. 2a). N501Y is the only mutation in B.1.1.7 RBD, but this variant did not show remarkable immune escape in both our (Fig. 2e) and prior studies(19, 20). Therefore, we tested several mutations in the other three critical sites, including K417N, L452R, E484K, and L452R/E484Q. The neutralization assay demonstrated that the L452R/E484Q (two key mutations of B.1.617) showed the strongest immune escape, followed by E484K, K417N, and L452R. The mean sera neutralization efficiency (Fig. 2b and 2f) demonstrated that the critical RBD mutations play a major role in the immune escape of the variants. Importantly, the cross-variant protective sera from the group 1 convalescents can also tolerate these critical mutations (Fig. 2f).

We do acknowledge some limitations of our studies. First, we did not determine the NT₅₀ of all the sera because of the limitation of the sample volume, especially for those with lower neutralizing activity. Second, we did not include all the possible mutations that can appear in the B.1.617 and its sub-lineages in consideration of the

sequence complexity of the variants circulating in India. Thus, future studies could be done to investigate whether other mutations on spike proteins can result in a leap of the immune escape ability of B.1.617 and other variants.

To our knowledge, the current study provides the first direct evidence that the potent anti-SARS-CoV-2 humoral immunity can last for at least one year in most convalescents to protect them against the original virus (WT or WT-D614G), which means the annually re-administration might be a feasible vaccination strategy to maintain the anti-SARS-CoV-2 humoral immunity. However, the convalescents and the vaccinated people are gradually losing protection against the constantly emerging immune escape variants. It remains to be determined whether re-administration of the variant-based or broadly neutralizing epitope-based vaccines can achieve effective cross-variant immunity. Overall, our study suggests that the timely update of the vaccines rather than the durability of the SARS-CoV-2 humoral immunity should be more of our concern.

Method

Sample collection

Convalescent sera were collected from a cohort of individuals with prior SARS-CoV-2 infection, collected between January 19, 2021 and January 26, 2021, 305 to 388 days after disease onset. And the illness severity, gender, and age range of donors were recorded. Sera from 10 healthy donors were also obtained. All blood donors provided written informed consent for participation in the study. These human

sera protocols were approved by the Ethics Committee of Hubei Provincial Center for Disease Control and Prevention, Wuhan, China (No. 2021-012-01). Sera of the RBD-hFc vaccinated mice (three times immunization) were collected seven weeks post the last immunization from the suborbital venous plexus. The mice sera protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Center for Animal Experiment, Wuhan University, Wuhan, China (No. WP20210007).

ELISA detection of SARS-CoV-2 S protein antibodies in the sera

The rapid IgG / IgM test was applied by 2019-nCoV IgG / IgM Detection Kit (Colloidal Gold-Based, Vazyme Biotech Co.,Ltd), which is based on the reactivity of IgG / IgM against SARS-CoV-2 S protein. The anti-RBD IgG level in sera was tested by SARS-CoV-2 (2019-nCoV) Spike RBD Antibody Titer Assay Kit (Sino Biological Inc), which is based on the reactivity of IgG against SARS-CoV-2 RBD. The competitive ability of ACE2 to RBD-binding of sera was tested through SARS-CoV-2 Neutralizing Antibodies Test Kit (ELISA, Wuxi BioHermes Bio & Medical Technology Co., Ltd), which is based on the competition between the neutralizing antibodies in sera and ACE2 to horseradish peroxidase labeled RBD protein (HRP-RBD). These ELISA detections were applied following the manufacturer's instructions.

Cell culture

HEK 293T (ATCC, CRL-1168), BHK-21(ATCC, CCL-10) and VERO E6 cells

(ATCC, CRL-1586) were cultured in Dulbecco's medium (DMEM; Gibco) supplemented with 10 % fetal bovine serum (FBS), 2.0mM L-Glutamine, 110 mg/L sodium pyruvate, and 4.5 g/L D-glucose. BHK-21-ACE2 (clone 7) which stably expression human ACE2 was generated based on BHK-21 through lentiviral transduction and maintained with puromycin at 1 µg/ml. I1-Hybridoma (CRL-2700) secreting a monoclonal antibody targeting VSV glycoprotein was cultured in Minimum Essential Medium with Earle's salts and 2.0 mM L-Glutamine (MEM; Gibco) supplemented with 10 % FBS. All cells were cultured at 37°C in 5 % CO₂ with regular passage of every 2-3 days.

Plasmids and protein

The DNA sequences of human codon-optimized S proteins from SARS-COV-2 variants (B.1.1.7, GISAID: EPI-ISL-601443; B.1.351, GISAID: EPI_ISL_678597; P.1, GISAID: EPI_ISL_906075; B.1.525, GISAID: EPI_ISL_1093472) and S protein mutations were commercially synthesized or generated by overlapping-PCR based mutagenesis using pCAGGS-SARS-CoV-2-S-C9 (gifted from Dr. Wenhui Li, National Institute of Biological Science, Beijing, China) as template and cloned into pCAGGS vector with C-terminal 18 aa truncation to improve VSV pseudotyping efficiency(21). The plasmid pCAGGS-SARS-CoV-2-RBD-hFc was constructed by inserting the RBD sequence (aa331-525) in to the pCAGGS vector for the expression of RBD-hFc recombinant protein in HEK 293T cells. The proteins were purified by protein A resin (GenScript) following the manufacturer's instructions.

273

274 **SARS-CoV-2 pseudovirus production and titration**

275 The pseudovirus packaged with spike proteins from the WT SARS-CoV-2 and
 276 the SARS-CoV-2 variants were produced according to a published protocol with
 277 minor modifications(22). Briefly, Vero-E6 cells were transfected with plasmids
 278 expressing different S proteins through the Lipofectamine 2000 (Biosharp, China).
 279 After 24 hrs, the transfected cells were inoculated with VSV-dG-fLuc (1×10^6
 280 TCID₅₀/ml) diluted in DMEM for 5 hrs at 37°C and then replenished with growth
 281 medium (DMEM with 10 % FBS) containing anti-VSV-G monoclonal antibody
 282 (I1-hybridoma, cultured supernatant, 1:20). 24 hrs later, the SARS-CoV-2
 283 pseudovirus-containing supernatant was harvested and clarified at 3000 r.p.m for 10
 284 min, aliquoted, and frozen at -80°C for storage. The 50 % tissue culture infectious
 285 dose (TCID₅₀) of pseudovirus was determined by a serial-dilution based infection
 286 assay on BHK-21-hACE2 cells and calculated according to the Reed-Muench
 287 method(22, 23).

288

289 **SARS-CoV-2 pseudovirus neutralization assay**

290 The SARS-CoV-2 pseudoviruses were incubated with serial-diluted sera at room
 291 temperature for 30 mins in 96-well white flat-bottom culture plates and then mixed
 292 with trypsinized BHK-21-hACE2 cells with the density of 2×10^4 /well. After 16 hrs,
 293 the medium of the infected cells was removed, and the cells were lysed with $1 \times$
 294 Bright-Glo Luciferase Assay reagent (Promega) for chemiluminescence detection

with a SpectraMax iD3 Multi-well Luminometer (Molecular devices). The 50 % neutralization dilution titer (NT50) was calculated by GraphPad Prism 7 software with nonlinear regression curve fitting (normalized response, variable slope).

Authentic SARS-CoV-2 neutralization assay

The SARS-CoV-2 WT strain (IVCAS 6.7512) and B.1.351 strain (NPRC 2.062100001)(24) were provided by the National Virus Resource, Wuhan Institute of Virology, Chinese Academy of Sciences, the SARS-CoV-2 B.1.1.7 strain (240108) was provided by HUBEI PROVINCIAL CENTR FOR DISEASE CONTROL AND PREVENTION. All SARS-CoV-2 authentic virus related experiments (S01321010A) were approved by the Biosafety Committee Level 3 (ABSL-3) of Wuhan University, Wuhan Institute of Virology and HUBEI PROVINCIAL CENTR FOR DISEASE CONTROL AND PREVENTION. In brief, sera were serially diluted in culture medium and mixed with 200 TCID₅₀ SARS-CoV-2 for 30 mins at room temperature. The mixture was then added to Vero E6 cells in 96-well plates and incubated for 24 hrs, and the cells were fixed with 4 % paraformaldehyde in PBS at room temperature for 1 h, permeabilized with 0.2 % Triton X-100 for 10 mins, and then blocked with 1 % BSA/PBS at 37 °C for 1 h. Cells were subsequently incubated with a mouse monoclonal antibody targeting SARS-CoV/SARS-CoV-2 Nucleocapsid (40143-MM05, Sino Biological) at 1:500 dilution at 37 °C for 1 h, and then incubated with 2 µg/ml of Alexa Fluor 594-conjugated goat anti-mouse IgG antibody (A-11032, Thermo Fisher Scientific) at 37 °C for 1 h. The nucleus was stained with Hoechst

33342. Images were acquired with an inverted fluorescence microscope (DMI8, Leica).

319 **Statistical analysis**

320 Data are presented as mean values with s.e.m. or s.d.. All statistical analyses
321 were done using GraphPad Prism 7. Differences between two independent samples
322 were evaluated by two-tailed Mann–Whitney U-tests, and $P < 0.05$ is considered
323 statistically significant. Differences between two related samples were evaluated by
324 paired two-tailed t-tests.

325 **Data availability**

326 All data are available in the manuscript or extended data.

328 **Acknowledgements**

329 This study was supported by grants from the National Science and Technology
330 Major Project (2018YFA0900801), China NSFC projects (32041007 and 32070160),
331 Fundamental Research Funds for the Central Universities (2042021kf0220 and
332 2042020kf0024), the Advanced Customer Cultivation Project of Wuhan National
333 Biosafety Laboratory (2021ACCP-MS10) and Special Fund for COVID-19 Research
334 of Wuhan University. We are grateful to Beijing Taikang Yicai Foundation for their
335 great support to this work.

337 **Author contributions**

338 K.L., Y.C., H.Y. and K.C. conceptualized the study design; F.H.M., F.X.Z., X.Y.C.,

B.H., J.Q.X and Y.Z.J. collected samples; Q.Y.L., Q.X., F.H.M., C.B.M., Z.Z., X.Y.C., M.G., X.W., Y.H.F., S.S. and C.W.K. did the laboratory tests; Q.Y.L., Q.X., F.H.M., Y.L.L., F.L., L.Z., K.X., C.W.K., F.D., H.Y. and Y.C. analysed the data; Q.Y.L., Q.X., F.H.M., H.Y., Y.C. and K.L. interpreted the results; Q.Y.L., Q.X., F.H.M., H.Y. and Y.C. wrote the initial drafts of the manuscript; Q.Y.L., K.C., H.Y., Y.C. and K.L. revised the manuscript; Y.L.L., F.L., L.Z., K.X., C.W.K., J.Q.X., Y.Z.J. and F.D. commented on the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information which includes Extended data figures and tables are available for this paper.

Reference:

1. L. Ni, F. Ye, M. L. Cheng, Y. Feng, Y. Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L. Sun, T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C. F. Qin, F. Chen, C. Dong, Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977 e973 (2020); published online EpubJun 16 (10.1016/j.immuni.2020.04.023).
2. J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R. Esterbauer, H. E. Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm, M. H. Dietrich, N. E. Scott, W. H. Tham, D. I. Godfrey, K. Subbarao, M. P. Davenport, S. J. Kent, A. K. Wheatley, Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nature medicine* **26**, 1428-1434 (2020); published online EpubSep (10.1038/s41591-020-0995-0).
3. P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D. Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng,

- 367 K. Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A
368 pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**,
369 270-273 (2020); published online EpubMar (10.1038/s41586-020-2012-7).
- 370 4. N. D. Grubaugh, E. B. Hodcroft, J. R. Fauver, A. L. Phelan, M. Cevik, Public health actions to
371 control new SARS-CoV-2 variants. *Cell* **184**, 1127-1132 (2021); published online EpubMar 4
372 (10.1016/j.cell.2021.01.044).
- 373 5. Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01. Technical Briefing 5.
374 *Public Health England*, (2020).
- 375 6. H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S.
376 Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T.
377 Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G.
378 Marais, M. Hsiao, S. Korsman, M.-A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals,
379 S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell,
380 J. Lourenço, L. C. J. Alcantara, S. L. K. Pond, S. Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C.
381 Williamson, T. de Oliveira, Emergence and rapid spread of a new severe acute respiratory
382 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South
383 Africa. *medRxiv*, 2020.2012.2021.20248640 (2020)10.1101/2020.12.21.20248640).
- 384 7. N. R. Faria, I. M. Claro, D. Candido, L. A. M. Franco, P. S. Andrade, Genomic characterisation of
385 an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. (2021).
- 386 8. E. A. Ozer, L. M. Simons, O. M. Adewumi, A. A. Fowotade, E. C. Omoruyi, J. A. Adeniji, T. J.
387 Dean, B. O. Taiwo, J. F. Hultquist, R. Lorenzo-Redondo, High prevalence of SARS-CoV-2 B.1.1.7
388 (UK variant) and the novel B.1.5.2.5 lineage in Oyo State, Nigeria. *medRxiv*, (2021);
389 published online EpubApr 17 (10.1101/2021.04.09.21255206).
- 390 9. P. D. Yadav, D. A. Nyayanit, R. R. Sahay, P. Sarkale, J. Pethani, S. Patil, S. Baradkar, V. Potdar, D. Y.
391 Patil, Isolation and characterization of the new SARS-CoV-2 variant in travellers from the
392 United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage. *Journal of travel medicine* **28**,
393 (2021); published online EpubFeb 23 (10.1093/jtm/taab009).
- 394 10. J. S. Turner, W. Kim, E. Kalaidina, C. W. Goss, A. M. Rauseo, A. J. Schmitz, L. Hansen, A. Haile,
395 M. K. Klebert, I. Pusic, J. A. O'Halloran, R. M. Presti, A. H. Ellebedy, SARS-CoV-2 infection
396 induces long-lived bone marrow plasma cells in humans. *Nature*, (2021); published online
397 EpubMay 24 (10.1038/s41586-021-03647-4).
- 398 11. Z. He, L. Ren, J. Yang, L. Guo, L. Feng, C. Ma, X. Wang, Z. Leng, X. Tong, W. Zhou, G. Wang, T.
399 Zhang, Y. Guo, C. Wu, Q. Wang, M. Liu, C. Wang, M. Jia, X. Hu, Y. Wang, X. Zhang, R. Hu, J.
400 Zhong, J. Yang, J. Dai, L. Chen, X. Zhou, J. Wang, W. Yang, C. Wang, Seroprevalence and
401 humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal,
402 population-level, cross-sectional study. *Lancet* **397**, 1075-1084 (2021); published online
403 EpubMar 20 (10.1016/S0140-6736(21)00238-5).
- 404 12. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S.
405 Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z.
406 Sheng, Y. Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
407 *Nature* **593**, 130-135 (2021); published online EpubMay (10.1038/s41586-021-03398-2).
- 408 13. M. Hoffmann, P. Arora, R. Gross, A. Seidel, B. F. Hornich, A. S. Hahn, N. Kruger, L. Graichen, H.
409 Hofmann-Winkler, A. Kempf, M. S. Winkler, S. Schulz, H. M. Jack, B. Jahrsdorfer, H.
410 Schrezenmeier, M. Muller, A. Kleger, J. Munch, S. Pohlmann, SARS-CoV-2 variants B.1.351 and

- 411 P.1 escape from neutralizing antibodies. *Cell* **184**, 2384-2393 e2312 (2021); published online
412 EpubApr 29 (10.1016/j.cell.2021.03.036).
- 413 14. S. Cao, Y. Gan, C. Wang, M. Bachmann, S. Wei, J. Gong, Y. Huang, T. Wang, L. Li, K. Lu, H. Jiang,
414 Y. Gong, H. Xu, X. Shen, Q. Tian, C. Lv, F. Song, X. Yin, Z. Lu, Post-lockdown SARS-CoV-2 nucleic
415 acid screening in nearly ten million residents of Wuhan, China. *Nature communications* **11**,
416 5917 (2020); published online EpubNov 20 (10.1038/s41467-020-19802-w).
- 417 15. V. Tchesnokova, H. Kulakesara, L. Larson, V. Bowers, E. Rechkina, D. Kisiela, Y. Sledneva, D.
418 Choudhury, I. Maslova, K. Deng, K. Kutumbaka, H. Geng, C. Fowler, D. Greene, J. Ralston, M.
419 Samadpour, E. Sokurenko, Acquisition of the L452R mutation in the ACE2-binding interface of
420 Spike protein triggers recent massive expansion of SARS-Cov-2 variants. *bioRxiv : the preprint*
421 *server for biology*, (2021); published online EpubMar 11 (10.1101/2021.02.22.432189).
- 422 16. D. Zhou, W. Dejnirattisai, P. Supasa, C. Liu, A. J. Mentzer, H. M. Ginn, Y. Zhao, H. M. E.
423 Duyvesteyn, A. Tuekprakhon, R. Nutalai, B. Wang, G. C. Paesen, C. Lopez-Camacho, J.
424 Slon-Campos, B. Hallis, N. Coombes, K. Bewley, S. Charlton, T. S. Walter, D. Skelly, S. F. Lumley,
425 C. Dold, R. Levin, T. Dong, A. J. Pollard, J. C. Knight, D. Crook, T. Lambe, E. Clutterbuck, S. Bibi,
426 A. Flaxman, M. Bittaye, S. Belij-Rammerstorfer, S. Gilbert, W. James, M. W. Carroll, P.
427 Klenerman, E. Barnes, S. J. Dunachie, E. E. Fry, J. Mongkolsapaya, J. Ren, D. I. Stuart, G. R.
428 Screaton, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
429 vaccine-induced sera. *Cell* **184**, 2348-2361 e2346 (2021); published online EpubApr 29
430 (10.1016/j.cell.2021.02.037).
- 431 17. A. W. D. Edridge, J. Kaczorowska, A. C. R. Hoste, M. Bakker, M. Klein, K. Loens, M. F. Jebbink, A.
432 Matser, C. M. Kinsella, P. Rueda, M. Ieven, H. Goossens, M. Prins, P. Sastre, M. Deijis, L. van
433 der Hoek, Seasonal coronavirus protective immunity is short-lasting. *Nature medicine* **26**,
434 1691-1693 (2020); published online EpubNov (10.1038/s41591-020-1083-1).
- 435 18. G. L. Wang, Z. Y. Wang, L. J. Duan, Q. C. Meng, M. D. Jiang, J. Cao, L. Yao, K. L. Zhu, W. C. Cao,
436 M. J. Ma, Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization. *The New*
437 *England journal of medicine*, (2021); published online EpubApr 6 (10.1056/NEJMc2103022).
- 438 19. P. Y. Shi, X. Xie, J. Zou, C. Fontes-Garfias, H. Xia, K. Swanson, M. Cutler, D. Cooper, V.
439 Menachery, S. Weaver, P. Dormitzer, Neutralization of N501Y mutant SARS-CoV-2 by
440 BNT162b2 vaccine-elicited sera. *Research square*, (2021); published online EpubJan 13
441 (10.21203/rs.3.rs-143532/v1).
- 442 20. X. Xie, Y. Liu, J. Liu, X. Zhang, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D.
443 Cooper, V. D. Menachery, S. C. Weaver, P. R. Dormitzer, P. Y. Shi, Neutralization of SARS-CoV-2
444 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nature*
445 *medicine* **27**, 620-621 (2021); published online EpubApr (10.1038/s41591-021-01270-4).
- 446 21. C. Schwegmann-Wessels, J. Glende, X. Ren, X. Qu, H. Deng, L. Enjuanes, G. Herrler,
447 Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and
448 a human coronavirus. *The Journal of general virology* **90**, 1724-1729 (2009); published online
449 EpubJul (10.1099/vir.0.009704-0).
- 450 22. J. Nie, Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q.
451 Sun, J. Liu, C. Fan, W. Huang, M. Xu, Y. Wang, Quantification of SARS-CoV-2 neutralizing
452 antibody by a pseudotyped virus-based assay. *Nature protocols* **15**, 3699-3715 (2020);
453 published online EpubNov (10.1038/s41596-020-0394-5).
- 454 23. M. Matumoto, A note on some points of calculation method of LD50 by Reed and Muench.

The Japanese journal of experimental medicine **20**, 175-179 (1949); published online EpubSep
(
24. C. Fengjuan, L. Bosheng, H. Peter, S. Yang, X. Wenbo, L. Nankun, L. Chunliang, K. Changwen, A
Case of New Variant COVID-19 First Emerging in South Africa Detected in Airplane Pilot —
Guangdong Province, China, January 6, 2021. *China CDC Weekly* **3**, 28-29
(2021)10.46234/ccdcw2021.007).

Figure legend

Fig. 1: The anti-RBD IgG level and neutralizing activity of sera from COVID-19 patients in Wuhan one-year after recovery.

a-e, Results of ELISA measuring the 248 convalescent COVID-19 patients' sera reactivity to SARS-CoV-2-RBD. The anti-RBD IgG level of the indicated groups (**a**, **c**). The competitive ability of ACE2 to RBD-binding of the indicated groups (**b**, **d**). **Comparison of the anti-RBD IgG and the competitive ability of ACE2 to RBD-binding in patients with different age (e)**. **f**, The neutralizing activity (WT-D614G) of the sera from convalescents with different severity was tested with the indicated dilution folds. Mean $\pm$ s.d. are shown in **a-d**. Mean $\pm$ s.e.m are shown in **e**. Statistical significance was determined using two-tailed Mann-Whitney U-tests, and no significant difference was found ($P > 0.05$). The horizontal dotted lines on **a** and **c** indicate the cut-off value (0.45, three times of the mean OD450 value of uninfected people's sera).

Fig. 2: The neutralizing activity of the convalescents' sera to SARS-CoV-2 variants.

a, The amino acid alterations in the S protein of SARS-CoV-2 variants tested in this study. **b**, The neutralizing activity of convalescents' sera at 100-fold dilution against pseudoviruses bearing S proteins from the indicated variants with WT-D614G as a control. **c-e**, Paired analysis of NT₅₀ values of convalescents' sera or RBD vaccinated mice sera against WT-D614G and variants. Serum group 1: relatively resistant (**c**). Serum group 2: sensitive (**d**). RBD-vaccinated mice sera (**e**). The serum group 1 and 2 were selected according to their tolerance to mutations in B.1.351. Statistical significance was determined using paired two-tailed t-tests. P values and mean fold changes in NT₅₀ values compared with WT-D614G are indicated. **f**, The neutralizing activity of convalescents' sera at 100-fold dilution against pseudoviruses bearing different S with indicated mutations. •, the relatively resistant serum sample. ★, the sensitive serum sample.

Fig. 3: The neutralizing activity of the convalescents' sera to authentic SARS-CoV-2 viruses.

a, The neutralizing activity of 30 representative sera against authentic SARS-CoV-2 WT strain at 20-fold and 100-fold dilution. The sera were grouped based on their neutralizing activity to WT-D614G pseudoviruses. **b-c**, The neutralizing activity of the selected sera (relatively resistant or sensitive against B.1.351 pseudovirus) against the indicated authentic SARS-CoV-2 viruses. SARS-CoV-2 N protein (red) in the infected cells was detected through immunofluorescence assay at 24 h post-infection. The nucleus was stained blue. Scale bar, 200 μ m. The serum sample number were indicated above the pictures.

497

498 **Extended data Fig. 1: The neutralizing activity of the convalescents' sera to WT-D614G and**
 499 **variants for NT₅₀ determination.**

500 Convalescents' sera were serially diluted and then were inoculated with 3×10^5 TCID₅₀
 501 pseudoviruses as indicated for 30 min at room temperature. BHK-21-hACE2 cells were infected
 502 by this mixture, followed by a chemiluminescence detection after 16 hrs. Mean $\pm$ s.d. (n=2) are
 503 shown. The NT₅₀ was calculated by GraphPad Prism 7 software with nonlinear regression curve
 504 fitting (normalized response, variable slope). The horizontal dotted lines on each graph indicate
 505 50 % and 0 % neutralization.

506

507 **Extended data Table 1: The clinical records and sera reactivity to SARS-CoV-2 of the**
 508 **convalescents in this study.**

509

Fig. 1

513 **Fig. 2**

A

	NTD												CTD													
	L18	T20	P26	Q52	A67	H69 & V70	D80	D138	Y144	R190	D215	L242-244	K417	E484	N501	A570	D614	H655	P681	A701	T716	F888	S982	T1027	D1118	V1176
WT-D614G																	G									
B.1.1.7 (the United Kingdom)					del			del							Y	D	G			H		I		A		H
P.1 (Brazil)	F	N	S					Y		S			T	K	Y		G	Y						I		F
B.1.525 (Nigeria)				R	V	del		del						K			G	Y				L				
B.1.351(South Africa)						A					G	del	N	K	Y		G			V						

B

C

D

E

F

516 **Fig. 3**